American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic ...

Activist Starboard took a position in Becton Dickinson, calling for the company to sell its life sciences business. The ...

BD (NYSE: BDX) announced that its board unanimously authorized management to pursue the separation of its Life Sciences ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and ...

Becton Dickinson (BDX) rose 2.4% in premarket trading as reports surface of potential separation of its $30 billion life ...

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of ...

The continued solid uptake of BD's products is expected to have driven fiscal first-quarter revenues despite transitory ...

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...

Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday, as the medical device ...